All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Malaria remains the most important parasitic infection in humans, causing an estimated 207 million cases and 627,000 deaths in 2010 \[[@ppat.1004667.ref001],[@ppat.1004667.ref002]\]. Mortality from severe *Plasmodium falciparum* malaria has decreased with use of intravenous artesunate, but case fatality rates remain at 8% and 15% for African children and Asian adults \[[@ppat.1004667.ref003],[@ppat.1004667.ref004]\]. Improved understanding of the pathogenesis of severe falciparum malaria may allow identification of new targets for adjunctive therapy.

Decreased nitric oxide (NO) bioavailability is associated with increased disease severity in African children as well as Asian adults and children with falciparum malaria \[[@ppat.1004667.ref005]--[@ppat.1004667.ref007]\], but the full reasons for this observation are not known. Mechanisms identified to date include low levels of L-arginine \[the substrate for NO synthase (NOS)\] \[[@ppat.1004667.ref006],[@ppat.1004667.ref008]\], impaired mononuclear cell NOS2 expression \[[@ppat.1004667.ref005]\], inhibition of NOS by ADMA \[[@ppat.1004667.ref009],[@ppat.1004667.ref010]\], and quenching of NO by increased plasma cell-free hemoglobin \[[@ppat.1004667.ref011]\]. In Asian adults with moderately severe falciparum malaria (MSM), L-arginine infusion increased endothelial NO and pulmonary NO bioavailability \[[@ppat.1004667.ref006]\]. However, a pilot trial of low-dose L-arginine infusion in adult severe falciparum malaria (SM) did not result in improvement in endothelial NO bioavailability or lactate clearance \[[@ppat.1004667.ref012]\]. While greater L-arginine clearance in severe malaria suggest that higher doses may be more effective \[[@ppat.1004667.ref012]\], additional mechanisms beyond L-arginine deficiency are likely to be involved.

Tetrahydrobiopterin (BH~4~) is an obligate co-factor for NO synthesis by NOS \[[@ppat.1004667.ref013],[@ppat.1004667.ref014]\]. BH~4~ stabilizes the homodimeric NOS enzyme and participates in L-arginine oxidation and heme-iron reduction for NO production. NOS lacking BH~4~ remains catalytically active, transferring electrons from NADPH to dioxygen to produce superoxide \[[@ppat.1004667.ref014],[@ppat.1004667.ref015]\]. Conversion of NOS catalysis from NO synthesis to superoxide production under conditions of low or absent BH~4~ is termed "uncoupling," meaning that NADPH consumption and oxygen activation are no longer "coupled" to BH~4~-dependent L-arginine oxygenation \[[@ppat.1004667.ref014],[@ppat.1004667.ref015]\]. In an oxidizing environment, NOS uncoupling may be related to the instability of BH~4~ because this reduced pterin spontaneously oxidizes to quininoid-BH~2~, which rapidly rearranges to the stable metabolite 7,8-dihydrobiopterin (BH~2~) that is inactive as a cofactor for NO synthesis. BH~2~ can be reduced back to BH~4~ via a tetrahydrofolate-dependent salvage pathway \[[@ppat.1004667.ref016]\]. However if BH~2~ levels rise at the expense of BH~4~ oxidation, BH~2~ competes with BH~4~ at the NOS active site leading to NOS uncoupling and superoxide production. In cardiovascular disease, an increased BH~4~/BH~2~ ratio (as opposed to the BH~4~ concentration alone) has been found to be the best correlate for endothelial cell-dependent NO synthesis \[[@ppat.1004667.ref014],[@ppat.1004667.ref015]\].

BH~4~ is also a co-factor for the enzyme phenylalanine hydroxylase that converts phenylalanine to tyrosine in the liver. We have found in both African children with cerebral malaria (CM) and Asian adults with SM that plasma phenylalanine levels are markedly increased \[[@ppat.1004667.ref017]\]. We hypothesized that in SM the systemic level of BH~4~, relative to the oxidized biopterin species (BH~2~ + B~0~), would be decreased. This could explain depression in both phenylalanine hydroxylase activity and NOS functionality in severe malaria. Biopterin oxidation states in plasma and urine (which reflect systemic levels) have not been measured in malaria. Therefore we undertook measurements of urinary BH~4~, BH~2~ and B~0~ in Indonesian adults with SM and MSM and compared these to levels in healthy controls and a group presenting with severe sepsis. We hypothesized that (a) BH~4~ levels and BH~4~/BH~2~ ratios would be decreased, and BH~2~ increased in proportion to malaria disease severity, and (b) decreased BH~4~/BH~2~ ratios would be associated with increased endothelial activation and impaired NO-dependent microvascular reactivity.

Results {#sec002}
=======

Patients {#sec003}
--------

The clinical features of these subjects have previously been described \[[@ppat.1004667.ref018]\]. We measured urinary pterin metabolites in their various oxidized states \[(including biopterin (B~0~), 7, 8 dihydrobiopterin (BH~2~), tetrahydrobiopterin (BH~4~), dihydroneopterin (NH~2~) and neopterin (N~0~)\] levels in 12 adults with severe malaria (SM) and 17 with moderately severe malaria (MSM), with 20 healthy adults (HCs) and 5 with severe sepsis (SS) as controls. In SM patients, 5 had single organ dysfunction (4 with cerebral malaria and 1 with acute renal failure), while the remaining 7 had two or more severity criteria. All SM and MSM patients received intravenous artesunate. In SS patients, two had pneumonia and gastroenteritis, and one each had pneumonia, gastroenteritis, and meningitis. There were 4 deaths in the SM group, and none in the MSM and SS patients. The baseline demographic details, clinical features, hematological and biochemical results of the patients are summarized in [Table 1](#ppat.1004667.t001){ref-type="table"}.

10.1371/journal.ppat.1004667.t001

###### Baseline demographics, clinical and laboratory measurements.

![](ppat.1004667.t001){#ppat.1004667.t001g}

                                                                                                           Healthy Controls    Moderately-severe malaria   Severe Malaria         Severe Sepsis
  -------------------------------------------------------------------------------------------------------- ------------------- --------------------------- ---------------------- -------------------
  Number                                                                                                   20                  17                          12                     5
  Age; years, (median, IQR)                                                                                29 (21--35)         28 (23--32)                 30 (21--37)            25 (24--26)
  Males; (number, percentage)                                                                              18 (90%)            11 (65%)                    9 (75%)                1 (20%)
  Days of fever before presentation (median, IQR)                                                          NA                  2 (2--5)                    3 (2--5)               2 (2--5)
  Systolic Blood Pressure; median (IQR), (mmHg)[\*](#t001fn001){ref-type="table-fn"}                       117 (113--126)      106 (100--115)              110 (101--132)         99 (94--101)
  Diastolic Blood Pressure; median (IQR), (mmHg)[\*](#t001fn001){ref-type="table-fn"}                      70 (65--75)         59 (57--64)                 64 (61--73)            64 (60--70)
  Pulse Rate; median (IQR), (beats/min)[\*](#t001fn001){ref-type="table-fn"}                               65 (60--73)         80 (75--88)                 90 (80--97)            104 (103--104)
  Pulse Oxygen Saturation; mean (range), (% saturation)                                                    99 (96--100)        98 (94--100)                96 (75--100)           99 (96--100)
  Temperature; mean (range) (°Celsius)[\*](#t001fn001){ref-type="table-fn"}                                36.1 (35--37)       37.1 (35.9--38.9)           37.0 (35.8--39.6)      37.2 (36.7--38.0)
  Leukocyte count; median (IQR), x10^3^/μL[\*](#t001fn001){ref-type="table-fn"}                            6.1 (4.5--6.8)      4.2 (3.7--5.8)              9.8 (7.4--12.0)        18.1 (15.4--22.1)
  Hemoglobin; mean (range), (g/dl)[\*](#t001fn001){ref-type="table-fn"}                                    12.8 (11.2--15.5)   11.5 (9.4--13.3)            12.0 (11.2--13.9)      9.2 (8.8--11.9)
  Platelet; median (IQR), x10^9^/L [\*](#t001fn001){ref-type="table-fn"}                                   153 (110--200)      53 (48--80)                 26 (20--98)            96 (76--201)
  Creatinine; median (IQR), (μmol/L)[\*](#t001fn001){ref-type="table-fn"} (normal range: 50 to 110 μmol)   NA                  87 (74--106)                182.5 (109--330)       80 (57--230)
  Lactate; median ((IQR), (mmol/L)[\*](#t001fn001){ref-type="table-fn"} (normal range: 0 to 2mmol)         NA                  1.08 (0.9--1.8)             3.11 (1.9--5.1)        1.31 (1.2--1.5)
  Parasite Density; Geometric Mean (95%CI), (parasite/μL)[\*](#t001fn001){ref-type="table-fn"}             NA                  14512 (8103--25989)         29269 (6453--132740)   NA
  Histidine Rich Protein 2; Median (IQR), (log~e~ ng/ml)                                                   NA                  2.76 (1.94--3.22)           4.26 (3.79--6.86)      NA

\*p\<0.05 (for ANOVA, Kruskal-Wallis or χ^2^ test comparing severe malaria, moderately-severe malaria, severe sepsis and healthy controls)

BH~4~, BH~2~, BH~4~/BH~2~ ratio, B~0~, NH~2~, N~0~ and clinical disease {#sec004}
-----------------------------------------------------------------------

BH~4~ was decreased in patients with SM (median 0.16 μmol/mmol creatinine; IQR 0.04--0.30) compared to those with MSM (0.27, IQR 0.19--0.41), SS (0.54; IQR 0.48--0.94), and controls (0.34; IQR 0.27--0.46); Kruskal-Wallis p\<0.001 ([Table 2](#ppat.1004667.t002){ref-type="table"}, [Fig. 1A](#ppat.1004667.g001){ref-type="fig"}). In contrast, BH~2~ was increased in SM (median 0.91 μmol/mmol creatinine; IQR 0.62--1.35) compared to MSM (0.67; IQR 0.52--0.76), SS (0.39; IQR 0.38--0.88) and HCs (0.52: IQR 0.43--0.69); Kruskal-Wallis p\<0.001 ([Table 2](#ppat.1004667.t002){ref-type="table"}, [Fig. 1B](#ppat.1004667.g001){ref-type="fig"}). The BH~4~/BH~2~ ratio was also decreased in patients with SM (median 0.17; IQR 0.04--0.32) compared to those with MSM (0.45, IQR 0.27--61), SS (1.03; IQR 0.54--2.38) and controls (0.66; IQR 0.43--1.07); Kruskal-Wallis p\<0.001 ([Table 2](#ppat.1004667.t002){ref-type="table"}, [Fig. 1C](#ppat.1004667.g001){ref-type="fig"}). Conversely NH~2~ and N~0~ levels were increased in SM compared to MSM, SS, and HCs (p\<0.001) ([Table 2](#ppat.1004667.t002){ref-type="table"}), but there were no significant differences in the total biopterin (BH~4~+BH~2~+B~0~) levels among groups (p = 0.1) ([Table 2](#ppat.1004667.t002){ref-type="table"}, [Fig. 1D](#ppat.1004667.g001){ref-type="fig"}). The ratio of reduced:oxidized neopterin (NH~2~:N~0~) was 4.4 in healthy controls compared to 2.0 in severe malaria (p = 0.002, [Table 2](#ppat.1004667.t002){ref-type="table"}). In the 29 patients with malaria, an increased BH~4~/BH~2~ ratio was associated with severe disease (p = 0.03), however no significant associations were found for BH~4~, BH~2~, B~0,~ total biopterin, NH~2,~ N~0~ and total neopterin. The risk of death in malaria was not associated with levels of any of the pterin metabolites. There was no association between serum creatinine and urinary BH~4~, BH~2~, N~0~ and NH~2~ in patients with malaria and in the groups with severe or uncomplicated disease. On controlling for blood creatinine, there was still a significant difference in urinary BH~2~ (p = 0.011) and BH~4~/BH~2~ (p = 0.04) levels but not BH~4~ between the groups.

10.1371/journal.ppat.1004667.t002

###### Microvascular reactivity, endothelial function and biopterin metabolite values among patient groups.

![](ppat.1004667.t002){#ppat.1004667.t002g}

                                                                                                                                 Healthy Controls    P value[†](#t002fn003){ref-type="table-fn"}   Moderately-severe malaria   P value[††](#t002fn004){ref-type="table-fn"}   Severe Sepsis       P value[†††](#t002fn005){ref-type="table-fn"}   Severe Malaria
  ------------------------------------------------------------------------------------------------------------------------------ ------------------- --------------------------------------------- --------------------------- ---------------------------------------------- ------------------- ----------------------------------------------- ---------------------
  Number                                                                                                                         20                                                                17                                                                         5                                                                   12
  Recovery StO~2~%second[\*](#t002fn002){ref-type="table-fn"} (StO~2recov~) Median (IQR) [\*](#t002fn002){ref-type="table-fn"}   3.5 (3.0--3.7)      0.04                                          3.2 (2.75--3.85)            0.1                                            3.1 (2.6--4.0)      0.05                                            2.8 (1.8--3.4)
  Reactive Hyperemia Peripheral Arterial Tonometry[\*](#t002fn002){ref-type="table-fn"}                                          1.76 (1.45--2.15)   0.06                                          1.77 (1.6--2.2)             0.04                                           1.56 (1.36--1.68)   0.2                                             1.38 (1.27--1.87)
  Tetrahydrobiopterin (BH~4~) [\*](#t002fn002){ref-type="table-fn"}                                                              0.34 (0.27--0.46)   0.006                                         0.27 (0.19--0.41)           0.08                                           0.54 (0.48--0.94)   0.008                                           0.16 (0.04--0.30)
  7, 8 dihydrobiopterin (BH~2~) [\*](#t002fn002){ref-type="table-fn"}                                                            0.52 (0.43--0.69)   0.002                                         0.67 (0.52--0.76)           0.03                                           0.39 (0.38--0.88)   0.05                                            0.91 (0.62--1.35)
  B~0~ Biopterin[\*](#t002fn002){ref-type="table-fn"}                                                                            0.01 (0--0.02)      0.02                                          0.02 (0.01--0.03)           0.08                                           0.03 (0.02--0.07)   0.08                                            0.06 (0.01--0.19)
  Urine Total Biopterins (BH~4~ + BH~2~ + B~0~)                                                                                  0.94 (0.75--1.18)   0.09                                          0.94 (0.76--1.17)           0.2                                            1.42 (1.35--1.45)   0.6                                             1.14 (0.89--1.84)
  BH~4~/BH~2~ ratio[\*](#t002fn002){ref-type="table-fn"}                                                                         0.67 (0.43--1.08)   0.001                                         0.45 (0.27--0.62)           0.01                                           1.03 (0.54--2.38)   0.003                                           0.18 (0.04--0.32)
  Dihydroneopterin (NH~2~) [\*](#t002fn002){ref-type="table-fn"}                                                                 1.73 (0.95--3.20)   0.001                                         6.9 (4.90--8.00)            0.6                                            3.02 (2.57--4.80)   0.1                                             6.2 (4.35--9.78)
  Neopterin (N~0~) [\*](#t002fn002){ref-type="table-fn"}                                                                         0.45 (0.21--0.72)   \<0.0001                                      1.86 (1.29--2.84)           0.03                                           0.85 (0.77--1.47)   0.02                                            4.16 (2.04--5.11)
  Total Neopterin (NH~2~ + N~0~) [\*](#t002fn002){ref-type="table-fn"}                                                           2.19 (1.16--3.90)   \<0.0001                                      8.65 (6.40--10.67)          0.2                                            3.87 (3.3--6.24)    0.03                                            10.78 (6.55--13.60)
  NH2/N~0~ Ratio                                                                                                                 4.44 (2.52--8)      0.002                                         3.57 (2.32--5.38)           0.03                                           3.23 (2.9--3.58)    0.17                                            1.98 (0.54--5.48)
  Phenylalanine (μmol/L) [\*](#t002fn002){ref-type="table-fn"}                                                                   54 (51--58)         0.03                                          101 (84--110)               0.09                                           114 (112--332)      0.2                                             176 (85--250)

Median and IQR unless otherwise stated. All pterin measurements are μmol/mmol creatinine

\*p\<0.05 (for ANOVA, Kruskal-Wallis or χ^2^ test comparing severe malaria, moderately-severe malaria, severe sepsis and healthy controls)

†Pairwise comparisons between each group and severe malaria using Wilcoxon-Mann-Whitney test: † control vs severe malaria;

†† moderately severe malaria vs severe malaria;

††† severe sepsis vs severe malaria.

![Urinary BH4, BH2 concentrations, BH4/BH2 ratios and Biopterin concentration in each group on enrollment (Kruskal-Wallis: p\<0.001). Horizontal bars represent pairwise comparisons between disease groups.\
A. Urine BH4 (μmol/mmol creatinine) concentrations in each group on enrollment. Horizontal lines indicate median values for each group. B. Urine BH2 (μmol/mmol creatinine) concentrations in each group on enrollment. Horizontal lines indicate median values for each group. C. BH4/BH2 ratio in each group on enrollment. Horizontal lines indicate median values for each group. D. Urine Biopterin (μmol/mmol creatinine) concentrations in each group on enrollment. Horizontal lines indicate median values for each group. Horizontal bars represent pairwise comparisons between disease groups.](ppat.1004667.g001){#ppat.1004667.g001}

BH~4~, BH~2~, BH~4~/BH~2~ ratio, and biomarkers of severity {#sec005}
-----------------------------------------------------------

Peripheral parasitemia was correlated with increasing BH~2~ (r = 0.46, p = 0.01) and N~0~ (r = 0.50, p = 0.006) levels, and parasite biomass (estimated using plasma HRP2) was positively correlated with BH~2~ (r = 0.44, p = 0.02), and inversely with the BH~4~/BH~2~ ratio (r = -0.41, p = 0.03) in all malaria patients but not after controlling for malarial disease severity. Increasing venous lactate was associated with higher BH~2~ levels (r = 0.48, p = 0.008) and a lower BH~4~/BH~2~ ratio (r = -0.43, p = 0.01) in all malaria patients but not after controlling for severity of disease.

**BH~4~, BH~2~, BH~4~/BH~2~ ratio, microvascular reactivity, and endothelial activation**. Similar to our previous published results \[[@ppat.1004667.ref018]\], microvascular reactivity and endothelial function were reduced in SM compared to MSM and HCs ([Table 2](#ppat.1004667.t002){ref-type="table"}). In all malaria patients, higher microvascular reactivity was associated with an increased BH~4~/BH~2~ ratio (r = 0.41, p = 0.03) and lower BH~2~ levels (r = -0.42, p = 0.024), with no association found for the other biopterin metabolites. The associations with the BH~4~/BH~2~ ratio and BH~2~ remained significant after controlling for disease severity (partial correlation coefficient = 0.34, p = 0.04 and partial correlation coefficient = -0.38, p = 0.04, respectively). Impaired endothelial function was also associated with increasing BH~2~ in all malaria patients (r = -0.42, p = 0.03) and those with severe malaria (r = -0.48, p = 0.04) but not in the MSM group alone. The association between endothelial function and BH~2~ remained significant after controlling for disease severity (partial correlation coefficient = -0.37, p = 0.04). Evaluation of markers of endothelial activation showed that ICAM-1 levels were positively associated with BH~2~ (r = 0.4, p = 0.02) and inversely associated with BH~4~ (r = -0.38, p = 0.04) and the BH~4~/BH~2~ ratio (r = -0.52, p = 0.003) in all malaria patients, but only with BH~4~/BH~2~ (r = -0.63, p = 0.03) in the SM group. The association between ICAM-1 with BH~4~ (partial correlation coefficient = -0.38, p = 0.035) and the BH~4~/BH~2~ ratio (partial correlation coefficient = -0.40, p = 0.03) remained significant after adjustment for malaria severity. The level of angiopoietin-2, another marker of malaria severity, was associated with increasing BH~2~ (r = 0.44, p = 0.02), but was not significant after adjusting for disease severity.

Plasma phenylalanine, and BH~4~, BH~2~, and the BH~4~/BH~2~ ratio {#sec006}
-----------------------------------------------------------------

Plasma phenylalanine levels were significantly increased in SM (median 176 μmol/L, IQR 85--250) compared to MSM (101μmol/L; IQR 84--110), SS (114μmol/L; IQR 112--332), and HCs (54μmol/L; IQR 51--58); Kruskal-Wallis p\<0.001 ([Table 2](#ppat.1004667.t002){ref-type="table"}). Among all patients with malaria, plasma phenylalanine levels were inversely related to the BH~4~/BH~2~ ratio (r = -0.44, p = 0.04, including after controlling for disease severity \[partial correlation coefficient = -0.38, p = 0.04\]) and positively related to BH~2~ levels (r = 0.39, p = 0.03, including after controlling for disease severity \[partial correlation coefficient = 0.48, p = 0.02\]), but not BH~4~, B~0~, NH~2,~ or N~0~.

Discussion {#sec007}
==========

In adults with falciparum malaria, urinary tetrahydrobiopterin (BH~4~) was decreased and 7, 8-dihydrobiopterin (BH~2~) increased in proportion to disease severity, and a decreased BH~4~/BH~2~ ratio was associated with an increased risk of severe disease. The BH~4~/BH~2~ ratio is a reliable correlate for endothelial cell-dependent NO synthesis in vascular diseases \[[@ppat.1004667.ref014]--[@ppat.1004667.ref016]\]. The finding of an association between decreased BH~4~/BH~2~ ratio and increased BH~2~ with impaired microvascular reactivity and increased endothelial activation is consistent with a mechanistic role for oxidative stress and vascular NOS dysfunction. The association of increased BH~2~ and low BH~4~/BH~2~ ratios with increased phenylalanine levels suggests that systemic deficiency of BH~4~ causes impaired phenylalanine hydroxylase function as well as NOS dysfunction in malaria.

We have previously shown decreased systemic NO production in both African children and Indonesian adults, proportional to disease severity \[[@ppat.1004667.ref005],[@ppat.1004667.ref006]\]. In adult falciparum malaria, there is also decreased endothelial and pulmonary NO bioavailability associated with low levels of the NOS substrate L-arginine \[[@ppat.1004667.ref006]\], increased levels of the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) \[[@ppat.1004667.ref010]\], NO quenching by cell-free hemoglobin \[[@ppat.1004667.ref011]\] and L-arginine reversible endothelial dysfunction in moderately severe malaria \[[@ppat.1004667.ref006]\]. The role of the key NOS cofactor, BH~4~, has not hitherto been shown in human malaria. In a recent murine severe malaria model, uncoupling of NOS with increased production of superoxide and impaired microvascular perfusion has been observed, and this was partially reversed by administration of intravenous BH~4~ \[[@ppat.1004667.ref019]\]. Our results suggest that uncoupling of NOS due to decreased BH~4~ bioavailability and increased BH~2~, is also a key mechanism of impaired NO bioavailability in human severe falciparum malaria and in pathogenesis of severe disease.

The physiological role of NOS is oxidation of L-arginine and oxygen reduction to produce NO and citrulline \[[@ppat.1004667.ref014],[@ppat.1004667.ref015],[@ppat.1004667.ref020]\]. BH~4~ regulates the coupling of the heme-oxygen intermediate to oxidation of L-arginine in NOS, and deficiency of BH~4~ as a co-factor can result in the output changing from NO to superoxide \[[@ppat.1004667.ref014],[@ppat.1004667.ref015],[@ppat.1004667.ref020]\]. Increased oxidative stress can convert BH~4~ to the oxidized form BH~2~, with the decrease in BH~4~ increasing superoxide, resulting in a feed forward cycle with further oxidization of BH~4~ to BH~2~ \[[@ppat.1004667.ref016]\]. Since BH~2~ can serve as a competitive inhibitor at the BH~4~ binding site in NOS, the BH~4~/BH~2~ ratio is likely to determine NOS coupling in malaria and determine the relative proportions of NO and superoxide production, as others have observed *in vitro* \[[@ppat.1004667.ref016]\].

Systemic bioavailability of BH~4~ depends on three pathways of pterin metabolism. First is *de novo* synthesis from GTP. A second is regeneration of BH~4~ from quinonoid dihydrobiopterin by dihydropteridine reductase (e.g in hepatocytes for phenylalanine hydroxylase activity) and third is the salvage of 7,8 dihydrobiopterin (BH~2~) back to BH~4~ via dihydrofolate reductase (important for NOS activity in endothelial cells). We found no diminution of total biopterins excreted, suggesting that mechanisms controlling overall biopterin production are not impaired. Instead the decrease in BH~4~ associated with severe malaria appeared to result from its oxidation coupled with inadequate reduction of BH~2~ to BH~4~. *In vivo* recycling of BH~2~ to BH~4~ is the main regulator of the BH~4~:BH~2~ ratio, which in turn controls NOS coupling \[[@ppat.1004667.ref016]\].

Our urine collection procedure allowed for capture of pterins, both biopterins and neopterins, in their excreted oxidation states. Our liquid chromatography methods allowed quantification of both dihydroneopterin and neopterin, the reduced and oxidized metabolites found in humans. This was of interest because these measurements provided information, in addition to biopterins redox status, on the partitioning of oxidized and reduced neopterins. We expected high total neopterin values in malaria and in septic patients and indeed this was found ([Table 2](#ppat.1004667.t002){ref-type="table"}). Elevated total neopterin has been reported previously and is the result of interferon-gamma-induced macrophage/monocyte activation with transcriptional induction of *GCH1* mRNA \[[@ppat.1004667.ref021]\]. Mononuclear phagocytes have extremely low pyruvoyl tetrahydropterin synthase (PTPS) activity. Consequently the product of GTPCH catalysis, 7,8 dihydroneopterin triphosphate, accumulates, is dephosphorylated intracellularly, and diffuses to extracellular fluid and then plasma as NH~2~. Neopterin in healthy controls is excreted primarily as reduced dihydroneopterin (NH~2~:N~0~ = 4.4). In patients with severe malaria, despite marked elevation in urinary levels of total neopterins, the portion excreted as NH~2~ fell significantly (NH~2~:N~0~ = 2.0). Importantly the oxidation of NH~2~ to N~0~ is non-enzymatic. This suggests a milieu of oxidative stress in SM. It provides additional support for the redox imbalance observed for the biopterins, that is a fall in the ratio of reduced to oxidized metabolites.

An increase in oxidative stress has been observed in Bangladeshi adults with severe falciparum malaria \[[@ppat.1004667.ref022]\]. This may explain the increased conversion of BH~4~ to BH~2~ as seen in this study, with the decreased BH~4~/BH~2~ ratio suggesting impaired recycling of BH~2~ to BH~4~ in severe malaria. Similar to certain cardiovascular diseases \[[@ppat.1004667.ref016]\], our results suggest it is the BH~4~/BH~2~ ratio and not BH~4~ or BH~2~ alone that reflects NOS coupling in malaria. A decreased BH~4~/BH~2~ ratio was associated with an increased risk of severe disease, while decreased BH~4~ or BH~2~ alone were not associated with risk of severe disease. The association of a decreased BH~4~/BH~2~ ratio with impaired microvascular reactivity and endothelial activation, both previously shown to be associated with increased mortality in malaria, suggests that NOS coupling has an important role in determining malaria severity.

Our results also show that there is impaired microvascular reactivity and increased endothelial activation in severe sepsis, as we have shown previously \[[@ppat.1004667.ref023],[@ppat.1004667.ref024]\]. However, it is notable that sepsis patients had *high* BH~4~ levels and *high* BH~4~/BH~2~ ratios compared to control subjects and malaria patients. The findings of increased BH~4~ levels in sepsis are similar to results from a previous study in which plasma biopterin levels were measured with high performance liquid chromatography \[[@ppat.1004667.ref025]\]. The mechanism(s) of impaired vascular function in these sepsis patients is unclear, but does not appear to be related to impaired BH~4~ bioavailability. Furthermore, the high BH~4~/BH~2~ ratio in sepsis indicates that the low BH~4~/BH~2~ ratio in severe falciparum malaria is not simply a result of a nonspecific pathogen-wide systemic inflammatory response.

Results from our study also suggest that, in addition to low plasma L-arginine concentrations, increased ADMA and impaired NOS2 expression in severe malaria \[[@ppat.1004667.ref005],[@ppat.1004667.ref006],[@ppat.1004667.ref008],[@ppat.1004667.ref010]\], decreased BH~4~ and increased BH~2~ can also affect NO bioavailability by altering NOS function in malaria. While increased L-arginine clearance in SM was seen in our pilot study of low dose L-arginine in severe malaria \[[@ppat.1004667.ref012]\], decreased BH~4~ and increased BH~2~ could result in low NO despite the presence of normal levels of L-arginine. Results of studies with higher doses of L-arginine in severe falciparum malaria (ACTRN 12612000571875) are awaited, but future studies in severe malaria targeting hypoargininemia may need to consider simultaneously increasing both L-arginine and BH~4~ to increase NO production by NOS. Use of intravenous BH~4~ in patients with endothelial dysfunction associated with hypercholesterolemia and smoking results in acute improvement in endothelial NO production \[[@ppat.1004667.ref026],[@ppat.1004667.ref027]\]. However, a randomized controlled trial of oral BH~4~ in patients with coronary artery diseases found that BH~4~ administration only resulted in increased conversion of BH~4~ to BH~2~ with no beneficial effects in clinical outcome \[[@ppat.1004667.ref028]\]. Using anti-oxidants as adjunctive agents in severe malaria could also increase the BH~4~/BH~2~ ratio, but a recent trial using intravenous N-acetylcysteine (without BH~4~) in adult severe malaria did not show a benefit in clinical outcomes \[[@ppat.1004667.ref022]\].

BH~4~ also plays a role as a co-factor for the enzyme phenylalanine hydroxylase, which converts phenylalanine to tyrosine \[[@ppat.1004667.ref017]\]. As previously shown \[[@ppat.1004667.ref017]\], both adults and children with clinical malaria are almost invariably hyperphenylalaninemic at presentation, which originally suggested a deficiency of BH~4~ in these patients. Blood levels of phenylalanine are normally tightly regulated between 30--80 μM by the BH~4~-dependent phenylalanine hydroxylase (PAH) in the liver \[[@ppat.1004667.ref017]\]. The skewed BH~4~/BH~2~ ratio and high BH~2~ levels in these subjects correlated significantly with hyperphenylalaninemia. Hyperphenylalaninemia in SM is a transient acute abnormality, and it is relatively mild compared to the high levels observed chronically in untreated infants with phenylketonuria, a condition leading to severe brain damage caused by the direct toxicity of phenylalanine \[[@ppat.1004667.ref029]\]. While it is not clear if the resulting hyperphenylalaninemia in malaria (especially cerebral malaria) is clinically relevant, it provides important supportive evidence for the functional significance of impaired BH~4~ bioavailability on BH~4~-dependent enzyme function in severe malaria.

This study has several limitations. The relatively small number of patients in each group and the small number of deaths in the SM group do not allow us to examine the independent effect of the biopterin metabolites on mortality or adjust for confounding variables. The numbers were however sufficient to demonstrate significant differences between groups. Also, the use of urinary measures of pterin metabolites as a measure of systemic biopterin bioavailability may not fully reflect intracellular concentrations in specific organs, though urinary biopterin quantitation has been shown to reflect systemic biopterin bioavailability \[[@ppat.1004667.ref030]--[@ppat.1004667.ref033]\]. It is possible that urinary BH~2~ and BH~4~ quantitation may be affected by renal function, although there was no association between blood creatinine and urinary BH~4~, BH~2~, N~0~ and NH~2~ in patients with malaria. Furthermore, measurement of the urine BH~4~/BH~2~ ratio is independent of creatinine excretion and is therefore not confounded by renal impairment. Importantly, the specialized collection techniques and assays we have used to measure urinary biopterin metabolite levels allow us to exclude artefactual *ex-vivo* oxidation.

In summary, the BH~4~/BH~2~ ratio is decreased in severe falciparum malaria but not in severe sepsis, and it is associated with an increased risk of severe disease, impaired microvascular function and endothelial activation, probably secondary to NOS uncoupling. The elevated levels of BH~2~ suggest that increased conversion of BH~4~ to BH~2~ due to increased oxidative stress and insufficient recycling of BH~2~ back to BH~4~ are the mechanisms of the low BH~4~/BH~2~ ratio in severe malaria. Our findings identify an additional mechanism of impaired NO bioavailability in severe falciparum malaria and pose an additional challenge to NOS-based adjunctive interventions to increase NO bioavailability in severe malaria.

Methods {#sec008}
=======

The study was undertaken at the Mitra Masyarakat Hospital, Timika, Papua, Indonesia, an area with unstable malaria transmission \[[@ppat.1004667.ref034]\]. Patients ≥18 years of age with severe (SM) or moderately severe (MSM) *Plasmodium falciparum* malaria, or severe sepsis (SS) were enrolled as previously described \[[@ppat.1004667.ref018]\]. SM was defined as peripheral parasitemia with ≥1 modified WHO criterion of severity \[[@ppat.1004667.ref035]\], and MSM was falciparum malaria with fever within the past 48 hours, parasite counts of \>1000/μL, requiring admission because of inability to tolerate oral therapy, but without WHO warning signs or severe criteria as previously described. Healthy controls (HC) were non-related hospital visitors without fever in the last 48 hours and no parasitemia. As an additional control for SM, patients with severe sepsis (SS) were also enrolled, defined as clinical evidence of infection, three or more features of the systemic inflammatory response syndrome, and evidence of one or more organ dysfunction, with or without septic shock, according to American College of Chest Physicians criteria, with no parasites by microscopy and a negative rapid diagnostic test for malaria \[[@ppat.1004667.ref018]\]. All patients were managed by non-study hospital physicians and treated accordingly with antimalarials and antibiotics using hospital protocols.

A standardized history and physical examination were documented. Venous blood was collected on enrolment to measure biomarkers of severity, including lactate and plasma histidine rich protein 2 (HRP2), a measure of parasite biomass \[[@ppat.1004667.ref036],[@ppat.1004667.ref037]\]. Plasma was obtained within 20 minutes and stored at -70°C for later quantitiation of the NO-dependent measures of endothelial activation, ICAM-1 and angiopoietin-2 by ELISA, as previously described \[[@ppat.1004667.ref037]\]. Parasite counts were determined by thick and thin film microscopy. Hemoglobin, biochemistry, acid-base parameters, and lactate were measured with a bedside analyzer (i-STAT Corp). Reactive hyperemia peripheral artery tonometry (RH-PAT) was used to measure endothelial NO bioavailability as previously described \[[@ppat.1004667.ref006],[@ppat.1004667.ref018]\]. RH-PAT uses finger probes to measure digital volume changes measured by a pressure transducer before and after application of an ischemic stress using a vascular cuff inflated to 200mmHg for 5 minutes followed by rapid cuff release. The RH-PAT index is a measure of the volume change and is at least 50% dependent on endothelial NO production. Near infrared resonance spectroscopy (NIRS) measurements were performed concurrently to assess microvascular reactivity on enrollment as reported before \[[@ppat.1004667.ref018]\]. In brief, a clinical spectroscope (InSpectra 650, Hutchinson Technology) was used noninvasively to assess microvascular reactivity by measuring differential absorption of oxy (O~2~Hb) and deoxyhaemoglobin (HHb), which is then displayed as tissue oxygen saturation (ratio of O~2~Hb/O~2~Hb+HHb signals). By inducing an ischemic stress as detailed above, microvascular reactivity is the rate of skeletal muscle reoxygenation, defined as the rate of increase in StO~2~ in the first 14 seconds after release of occlusion. According to Beer's law, this is confined to arterioles, capillaries, and venules of skeletal muscle with minimal interference from skin blood flow and myoglobin.

Measurement of urine pterin compounds {#sec009}
-------------------------------------

Measurement of urine pterin concentrations, expressed as biopterins and neopterins in micromoles per millimole urine creatinine are used for diagnosis of gene mutations leading to BH~4~ synthesis, recycling and salvage deficiencies and reflect systemic pterin bioavailability \[[@ppat.1004667.ref030]--[@ppat.1004667.ref033]\]. BH~4~ is unstable and spontaneously oxidizes to its inactive metabolites, dihydrobiopterin (BH~2~) and to a lesser extent fully oxidized biopterin (B~0~) \[[@ppat.1004667.ref038],[@ppat.1004667.ref039]\]. To prevent ex vivo spontaneous oxidation, urine was collected, via voluntary micturition or immediately after insertion of a Foley catheter, directly into vials containing the antioxidant pterin stabilizers 1,4-dithioerythritol (DTE) and diethylenetriaminepentaacetic acid (DETAPAC) \[[@ppat.1004667.ref038],[@ppat.1004667.ref039]\] (as described in [S1](#ppat.1004667.s001){ref-type="supplementary-material"}). Urine was then frozen at -70°C, and shipped in liquid nitrogen to Medical Neurogenetics Laboratories, LLC, Atlanta, GA United States. Concentrations of biopterin, 7,8-dihydrobiopterin, 5,6,7,8-tetrahydrobiopterin, and neopterin were quantified by high performance liquid chromatography using sequential electrochemical and fluorescence detection, as previously described \[[@ppat.1004667.ref038],[@ppat.1004667.ref039]\]. Concentrations of pterin metabolites were normalized to creatinine concentrations in millimoles.

Statistical methods {#sec010}
-------------------

Statistical analysis was performed using STATA 11 software. The sample size for the patients with severe malaria was calculated from our previous study comparing RH-PAT in adults with severe and uncomplicated malaria with controls \[[@ppat.1004667.ref006]\]. Using the difference and standard deviations found in RH-PAT index between severe malaria and controls, we estimated that a sample size of 14 in each group would have 80% power to detect a 25% difference between these two groups. Intergroup differences among malaria (MSM and SM) and controls were compared by ANOVA or Kruskal-Wallis test, where appropriate, with Wilcoxon Rank-Sum test used for pairwise comparisons. Pearson's or Spearman's correlation coefficients were determined depending on normality of distributions. Partial correlation coefficients were calculated adjusting for malaria disease severity. Logistic regression was used to determine the association between binary outcomes and goodness-of-fit was assessed by the Hosmer-Lemeshow test. A two-sided value of p\<0.05 was considered significant.

Ethics statement {#sec011}
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